TNFRSF4 and neoplasm: Both FMD, anti-OX40/anti-PD-L1 treatment and their combinations reduce the percentage of the immunosuppressive M-MDSC (CD11b+Ly6Chigh) in the tumor bed compared to the standard diet group (Fig. 3C), whereas PMN-MDSC (CD11b+Ly6ClowLy6Ghigh) display a trend for enrichment only in the AL group treated with ICIs (Fig. 3D).